Humacyte, Inc. (HUMA)
(Delayed Data from NSDQ)
$5.25 USD
-0.14 (-2.60%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $5.25 0.00 (0.00%) 6:00 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.25 USD
-0.14 (-2.60%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $5.25 0.00 (0.00%) 6:00 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
Humacyte's (HUMA) ATEV BLA Review Period Extended by FDA
by Zacks Equity Research
Humacyte's (HUMA) Biologic License Application for its ATEV faces a delay as the FDA extends its review timeline, recognizing the product's potential impact on vascular trauma treatment.
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Humacyte, Inc. (HUMA) stood at $7.85, denoting a -1.13% change from the preceding trading day.
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Humacyte, Inc. (HUMA) closed the most recent trading day at $8.29, moving -0.72% from the previous trading session.
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
Humacyte, Inc. (HUMA) reachead $5.17 at the closing of the latest trading day, reflecting a -1.34% change compared to its last close.
Should You Buy Humacyte (HUMA) Ahead of Earnings?
by Zacks Equity Research
Humacyte (HUMA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma
by Zacks Equity Research
Humacyte (HUMA) gains 16% as the FDA accepts its BLA for the HAV bioengineered tissue to treat vascular trauma under Priority Review. A final decision is expected in August 2024.
Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 0% and 68.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 0% and 14.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aeglea (AGLE) delivered earnings and revenue surprises of -5.26% and 16.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 1,860% and 51.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?
by Zacks Equity Research
Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Humacyte (HUMA) Completes Enrollment in HAV Technology Study
by Zacks Equity Research
Humacyte (HUMA) surges as it completes patient enrollment in a late-stage clinical study on the human acellular vessel product for vascular access in hemodialysis patients.
Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 12.50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.90% and 131.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 0.65% and 8.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -19.05% and 88.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Prometheus Biosciences, Inc. (RXDX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -1.12% and 26.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 42.31% and 11.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See an 85% Upside in Humacyte, Inc. (HUMA): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at an 84.8% upside potential for Humacyte, Inc. (HUMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Henry Schein (HSIC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Henry Schein (HSIC) and Humacyte, Inc. (HUMA) have performed compared to their sector so far this year.